Cebrotonin Dosage/Direction for Use

The dosage depends on type and severity of the clinical picture and the patient's response to the therapy. Unless otherwise prescribed by the physician the following dosage guidelines apply: For adults: 3 times daily 1 f/c tablet of this product (equiv. to 2.4 g piracetam). On special medical prescription the dose can be raised to 3 times daily 2 f/c tablets of this product (equiv. to 4.8 g piracetam).
Dose adjustment in elderly patients: In elderly patients with renal impairment, the dosage is determined by the attending physician. Periodic monitoring of creatinine clearance by the physician is required during long-term treatment of elderly patients to adjust the dose if needed.
Dose adjustment in patients with impaired renal function: As piracetam is exclusively eliminated via the kidneys, increased plasma levels may be produced in case of reduced renal function. Piracetam is contraindicated in severe renal impairment (renal creatinine clearance of less than 20 ml per minute). The daily dose must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination using the following formula: (See equation and table.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Dose adjustment in patients with impaired liver function: Piracetam is not metabolised in the liver. For patients with reduced liver function no other dosage guidelines apply. In patients with impaired liver as well as impaired renal function dosage is determined by the attending physician.
This product should be taken with one glass of liquid (e.g. water), for reasons of expediency together with or directly after the meals. The duration of treatment depends on the physician's decision. In case of a supporting treatment of syndromes of dementia it has to be verified after three months whether a further treatment is still indicated.